Suppr超能文献

用于在级联攻击中对肝细胞癌进行多维协同治疗的响应性活性氧增强前药杂交纳米组装体

Responsive ROS-Augmented Prodrug Hybridization Nanoassemblies for Multidimensionally Synergitic Treatment of Hepatocellular Carcinoma in Cascade Assaults.

作者信息

Zeng Yingjie, Cao Yuening, Ren Senmiao, Zhang Chaozheng, Liu Jianan, Liu Ke, Wang Yan, Chen Hongyu, Zhou Fengjiao, Yang Xiuli, Ge Xian, Zhang Tingting, Wang Tianbao, He Yao, Li Defang, Zhang Chuantao, Lu Jun

机构信息

State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.

Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.

出版信息

Adv Sci (Weinh). 2025 May 5:e2501420. doi: 10.1002/advs.202501420.

Abstract

The rapid deterioration and progression of hepatocellular carcinoma (HCC) is intimately associated with copper ion overload, and integrating the cuproptosis mechanism for the treatment of HCC presents a promising prospect. Nevertheless, cell death complexity renders efficient removal of all HCC cells insufficient solely relying on the cuproptosis pathway. Herein, the GSH-responsive prodrug hybridization nanoassembly CA-4S@ES-Cu is exploited, which targets the delivery of copper ions to mitochondria via Elesclomol, contributing to mitochondrial dysfunction and evoking cuproptosis. Simultaneously, CA-4S depletes GSH to release CA-4, disrupting microtubule function and suppressing HCC cell proliferation and angiogenesis, to realize a dual attack against copper ion-mediated deterioration and metastasis of HCC. Furthermore, both in the HCC mouse model synergistically elicit oxidative stress to amplify the cuproptosis effect and release activated immunogenetic cell death to initiate a vigorous antitumor immune response in cascade assault modality. Conclusively, the multilevel synergistic assault penetrates the limitations of single therapy and implements a multidimensional targeted treatment for HCC.

摘要

肝细胞癌(HCC)的快速恶化和进展与铜离子过载密切相关,整合铜死亡机制用于治疗HCC具有广阔前景。然而,细胞死亡的复杂性使得仅依靠铜死亡途径无法有效清除所有HCC细胞。在此,开发了谷胱甘肽响应性前药杂交纳米组装体CA-4S@ES-Cu,其通过艾立布林将铜离子靶向递送至线粒体,导致线粒体功能障碍并引发铜死亡。同时,CA-4S消耗谷胱甘肽以释放CA-4,破坏微管功能并抑制HCC细胞增殖和血管生成,以实现对铜离子介导的HCC恶化和转移的双重攻击。此外,在HCC小鼠模型中,二者协同引发氧化应激以放大铜死亡效应并释放活化的免疫原性细胞死亡,从而以级联攻击方式启动强烈的抗肿瘤免疫反应。总之,这种多层次协同攻击突破了单一疗法的局限性,实现了对HCC的多维靶向治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验